doi: 10.1016/0304-4165(78)90216-7.
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture
- PMID: 152655
- DOI: 10.1016/0304-4165(78)90216-7
Item in Clipboard
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture
Biochim Biophys Acta.
.
Abstract
An inhibitor present in placenta and released in placental tissue culture forms specific complexes with each of two molecular forms of urokinase. Autoradiography demonstrated that the inhibitor shifted the electrophoretic position of 125I-labelled urokinase. It did not change the migration of diisopropyl-fluorophosphate-inactivated 125I-labelled urokinase, thereby indicating complex formation dependent on active serine site in urokinase. The inhibitor had a strong neutralizing effect on the plasminogen activators released from human ovarian carcinoma in tissue culture. The placental inhibitor might prove useful in inhibiting the fibrinolytic process necessary for proliferation of tumour vessels.
Similar articles
-
An inhibitor of plasminogen activation from human placenta. Purification and characterization.J Biol Chem. 1987 Mar 15;262(8):3646-53. J Biol Chem. 1987. PMID: 3102492
-
Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase.Biochim Biophys Acta. 1982 Jun 24;704(3):450-60. doi: 10.1016/0167-4838(82)90067-x. Biochim Biophys Acta. 1982. PMID: 7052133
-
Properties of three different molecular forms of the alpha 2 plasmin inhibitor.Eur J Biochem. 1981 Nov;120(1):105-12. doi: 10.1111/j.1432-1033.1981.tb05675.x. Eur J Biochem. 1981. PMID: 6458494 No abstract available.
-
Characterization of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor.Biochem J. 1985 Aug 15;230(1):109-16. doi: 10.1042/bj2300109. Biochem J. 1985. PMID: 2932100 Free PMC article.
-
The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.Ann N Y Acad Sci. 1992 Dec 4;667:13-31. doi: 10.1111/j.1749-6632.1992.tb51591.x. Ann N Y Acad Sci. 1992. PMID: 1339241 Review. No abstract available.
Cited by
-
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.Br Med J (Clin Res Ed). 1985 May 18;290(6480):1453-6. doi: 10.1136/bmj.290.6480.1453. Br Med J (Clin Res Ed). 1985. PMID: 3922531 Free PMC article.
-
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.J Cell Biol. 1987 Apr;104(4):1085-96. doi: 10.1083/jcb.104.4.1085. J Cell Biol. 1987. PMID: 3104349 Free PMC article.
-
Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall.J Clin Pathol. 1985 Feb;38(2):140-5. doi: 10.1136/jcp.38.2.140. J Clin Pathol. 1985. PMID: 3881480 Free PMC article.
-
Plasminogen activator and protease inhibitor activities in isolated rat thymocytes.Mol Cell Biochem. 1985 Mar;66(2):137-44. doi: 10.1007/BF00220781. Mol Cell Biochem. 1985. PMID: 3157048
-
The use of glycylhistidyllysine in culture systems.In Vitro. 1981 Jun;17(6):459-66. doi: 10.1007/BF02633506. In Vitro. 1981. PMID: 7021400 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
